Alphatec Holdings Reports Strong 25% Revenue Growth and Shift to Positive Operating Cash Flow in Full-Year 2025

summarizeSummary

Alphatec Holdings' 2025 Annual Report confirms robust financial performance, highlighted by a significant 25% increase in revenue and a crucial shift to positive cash flow from operations. This marks a substantial improvement in the company's financial health and operational efficiency. The report also details a major debt refinancing, including the issuance of $405 million in 2030 convertible notes and the repurchase of 80% of its 2026 notes, which strengthens the balance sheet and extends debt maturities. While net losses persist, the reduction from the prior year, coupled with strong top-line growth and improved cash generation, indicates a positive trajectory. The increase in authorized common stock provides flexibility for future capital needs. This filing provides the full audited details following a preliminary announcement, solidifying the positive outlook.

check_boxKey Events

• Strong Revenue Growth

  Total revenue increased by 25% to $764.2 million for the year ended December 31, 2025, up from $611.6 million in 2024, driven by increased surgeon adoption and product portfolio expansion.

• Shift to Positive Operating Cash Flow

  Operating activities provided net cash of $45.2 million in 2025, a significant improvement from using $44.7 million in 2024, indicating enhanced operational efficiency and financial stability.

• Debt Refinancing and Maturity Extension

  The company issued $405.0 million in 0.75% Convertible Senior Notes due 2030 and repurchased 80% of its 2026 Convertible Notes for $268.4 million, extending debt maturities and managing capital structure.

• Decreased Net Loss

  Net loss decreased to $(143.4) million in 2025 from $(162.1) million in 2024, reflecting progress towards profitability.

auto_awesomeAnalysis

Alphatec Holdings' 2025 Annual Report confirms robust financial performance, highlighted by a significant 25% increase in revenue and a crucial shift to positive cash flow from operations. This marks a substantial improvement in the company's financial health and operational efficiency. The report also details a major debt refinancing, including the issuance of $405 million in 2030 convertible notes and the repurchase of 80% of its 2026 notes, which strengthens the balance sheet and extends debt maturities. While net losses persist, the reduction from the prior year, coupled with strong top-line growth and improved cash generation, indicates a positive trajectory. The increase in authorized common stock provides flexibility for future capital needs. This filing provides the full audited details following a preliminary announcement, solidifying the positive outlook.